Significant inter-individual variability on the effect of vitamin K to reverse overanticoagulation has been identified. Genetic polymorphisms of the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene might explain in part this variability. The objective of this study was to evaluate the influence of VKORC1 −1639G>A and 3730G>A polymorphisms on the effect of oral vitamin K supplementation in overanticoagulated patients. We performed an interventional trial of oral vitamin K supplementation in over-anticoagulated outpatients (international normalized ratio [INR] ≥ 4). Subjects received vitamin K (2.5–5.0 mg) according to baseline INR and were genotyped by real time polymerase chain reaction (PCR). INR values were determined at 3, 6, 24 and 72 h after supplementation. We evaluated 33 outpatients, 61 % were males, with a mean age of 62 ± 12 years old. There was a significant decrease in INR values over time for both polymorphisms after oral vitamin K. At 3 h after supplementation, patients carrying the G allele for the −1639G>A polymorphism had a greater decrease in INR values compared to AA patients (p < 0.05 for difference among groups; p < 0.001 for time variation; p = 0.001 for time × group interaction), with differences of −1.01 for GG versus AA (p = 0.003) and −0.84 for GA versus AA (p = 0.024). Mean INR value at 24 h was 1.9 ± 0.6 and at 72 h was 2.1 ± 0.7, with no differences among genotypes. No significant interaction was identified between the 3730G>A polymorphism and vitamin K supplementation. Our study indicated that the VKORC1 −1639G>A polymorphism plays a role in the response to acute vitamin K supplementation in over-anticoagulated patients, with faster decrease of INR value in patients carrying the G allele.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:8S–21S
Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE (1998) Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 279:657–662
Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer FJM, Vandenbroucke JP, Briët R (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17
Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians evidence. Chest 141(2 Suppl):e152S–e184S
Kamali F, Wynne H (2010) Pharmacogenetics of warfarin. Annu Rev Med 61:63–75
Sconce EA, Kamali F (2006) Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol 77:457–462
Franco V, Polanczyk CA, Clausell N, Rohde LE (2004) Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 116:651–656
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333
Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K et al (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P4502C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120:181–186
D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649
Giansante C, Fiotti N, Altamura N, Pitacco P, Consoloni L, Scardi S, Mazzone C, Grassi G, Pandullo C, Di Lenarda A (2012) Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up. J Thromb Thrombolysis 34:506–512
Sconce EA, Avery PJ, Wynne HA, Kamali F (2008) Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. Thromb Haemost 6:1226–1228
Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH (2011) Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 72:442–450
Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC (2012) Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol 158:256–261
Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Gen 121:23–34
Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. International warfarin pharmacogenetics consortium. N Engl J Med 360:753–764
Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M, Palareti G (2012) A new warfarin dosing algorithm including VKORC1 3730 G>A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 68:1167–1174
Rohde LE, de Assis MC, Rabelo ER (2007) Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 10:1–5
Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE (2009) Improved oral anticoagulation after a dietary vitamin K-guided strategy—a randomized controlled trial. Circulation 120:1115–1122
Rombouts EK, Rosendaal FR, Van der Meer FJ (2010) Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 149:598–605
Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC (2010) Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 104:755–759
Makris M, van Veen JJ, Maclean R (2010) Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 29:171–181
Rombouts EK, Rosendaal FR, Van Der Meer FJM (2007) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043–2048
Gebuis EPA, Rosendaal FR, van Meegen E, van der Meer FJM (2011) Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica 96:583–589
Instittute of Medicine (2001) Dietary reference intakes for vitamin A, vitamin K, arsenic boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. National Academic, Washington
Rombouts EK, Rosendaal FR, Van Der Meer FJL (2009) Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost 101:552–556
Presse N, Kergoat MJ, Ferland G (2011) High usual dietary vitamin K intake is associated with low relative variability in vitamin K intake: implications for anticoagulant therapy. Br J Haematol 153:129–143
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Zuchinali, P., Souza, G.C., Aliti, G. et al. Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. J Thromb Thrombolysis 37, 338–344 (2014). https://doi.org/10.1007/s11239-013-0947-3
- Vitamin K